Abstract
Remarkable technological advances have been recently made to treat cancer, such as site-specific delivery of drugs. Both passive and active targeting are expected to targeting only cancer cells and thus avoiding deleterious effect on healthy cells. Targeting also reduces the effective dose and dosing frequency versus classical delivery. This chapter reviews passive and active targeting of drugs to tumors. We also present novel targeting strategies to overcome issues associated with the tumor microenvironment and eradicating the cancerous cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Andtbacka RHI, Collichio FA, Amatruda Senzer TNN, Chesney J, Delman KA, Spitler LE, Puzanov I, Doleman S, Ye Y (2013) OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 31:18. https://doi.org/10.1200/jco.2013.31.18_suppl.lba9008
Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P (2011) Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 6:e24374. https://doi.org/10.1371/journal.pone.0024374
Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8:604–617. https://doi.org/10.1038/nrc2353
Badera T, Stoll B, Tooredman J, Capen D, Tomaso E, Jain R (2004) Cancer cells compress intratumoral vessels. Nature (London) 427:695. https://doi.org/10.1038/427695a
Barua S, Mitragotri S (2014) Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today 9:223–243. https://doi.org/10.1016/j.nantod.2014.04.008
Begley CG, Ellis LM (2012) Raise standards for preclinical cancer research. Nature 483:531–533. https://doi.org/10.1038/483531a
Behera A, Padhi S (2020) Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review. Environ Chem Lett 18:1557–1567. https://doi.org/10.1007/s10311-020-01022-9
Behera A, Mittu B, Padhi S, Patra N, Singh J (2020) Bimetallic nanoparticles: Green synthesis, applications, and future perspectives. In: Abd-Elsalam K (ed) Multifunctional hybrid nanomaterials for sustainable agri-food and ecosystems. Elsevier, pp 639–682. https://doi.org/10.1016/B978-0-12-821354-4.00025-X
Berry C (2008) Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine 3:3. https://doi.org/10.2217/17435889.3.3.357
Bharti R, Dey G, Banerjee I, Dey KK, Parida S, Kumar BP, Das CK, Pal I, Mukherjee M, Misra M (2017) Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy. Cancer Lett 388:292–302. https://doi.org/10.1016/j.canlet.2016.12.021
Biffi S, Voltan R, Bortot B, Zauli G, Secchiero P (2019) Actively targeted nanocarriers for drug delivery to cancer cells. Expert Opin Drug Deliv 16:481–496. https://doi.org/10.1080/17425247.2019.1604679
Bilan R, Nabiev I, Sukhanova A (2016) Quantum dot-based nanotools for bioimaging, diagnostics, and drug delivery. ChemBioChem 17:2103–2114. https://doi.org/10.1002/cbic.201600357
Bozec A, Gros F-X, Penault-Llorca F, Formento P, Cayre A, Dental C, Etienne-Grimaldi M-C, Fischel J-L, Milano G (2008) Vertical VEGF targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 44:1922–1930. https://doi.org/10.1016/j.ejca.2008.07.013
Brahimi-Horn MC, Pouysségur J (2007) Oxygen, a source of life and stress. FEBS Lett 581:3582–3591. https://doi.org/10.1016/j.febslet.2007.06.018
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang T-H, Moon A, Patt R (2011) Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477:99–102. https://doi.org/10.1038/nature10358
Brennan FR, Shaw L, Wing MG, Robinson C (2004) Preclinical safety testing of biotechnology-derived pharmaceuticals. Mol Biotechnol 27:59–74. https://doi.org/10.1385/MB:27:1:59
Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389–395. https://doi.org/10.1038/74651
Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69:4–10. https://doi.org/10.1159/000088478
Chamundeeswari M, Jeslin J, Verma ML (2019) Nanocarriers for drug delivery applications. Environ Chem Lett 17:849–865. https://doi.org/10.1007/s10311-018-00841-1
Chen L-D, Liu J, Yu X-F, He M, Pei X-F, Tang Z-Y, Wang Q-Q, Pang D-W, Li Y (2008) The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials 29:4170–4176. https://doi.org/10.1016/j.biomaterials.2008.07.025
Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, Li J, Yong E-L, Xu HE, Melcher K (2013) Structural basis for molecular recognition of folic acid by folate receptors. Nature 500:486–489. https://doi.org/10.1038/nature12327
Cho H-J, Yoon HY, Koo H, Ko S-H, Shim J-S, Lee J-H, Kim K, Kwon IC, Kim D-D (2011) Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials 32:7181–7190. https://doi.org/10.1016/j.biomaterials.2011.06.028
Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Jeong SY (2010) Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31:106–114. https://doi.org/10.1016/j.biomaterials.2009.09.030
Choi KY, Saravanakumar G, Park JH, Park K (2012) Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B: Biointerfaces 99:82–94. https://doi.org/10.1016/j.colsurfb.2011.10.029
Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, Jérôme C, Marchand-Brynaert J, Feron O, Préat V (2009) Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release 140:166–173. https://doi.org/10.1016/j.jconrel.2009.08.011
Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146. https://doi.org/10.1016/j.jconrel.2010.08.027
Das M, Mohanty C, Sahoo SK (2009) Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 6:285–304. https://doi.org/10.1517/17425240902780166
Dasargyri A, Kümin CD, Leroux JC (2017) Targeting nanocarriers with anisamide: fact or artifact? Adv Mater 29:1603451. https://doi.org/10.1002/adma.201603451
Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324. https://doi.org/10.1158/1078-0432.CCR-05-1634
Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22. https://doi.org/10.1038/nrc2748
Dienst A, Grunow A, Unruh M, Rabausch B, Nör JE, Fries JW, Gottstein C (2005) Specific occlusion of murine and human tumor vasculature by VCAM-1–targeted recombinant fusion proteins. J Natl Cancer Inst 97(10):733–747. https://doi.org/10.1093/jnci/dji130
Ding H-M, Ma Y-Q (2013) Controlling cellular uptake of nanoparticles with pH-sensitive polymers. Sci Rep UK 3:2804. https://doi.org/10.1038/srep02804
Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A (2006) Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98(5):335–344. https://doi.org/10.1093/jnci/djj070
ElBayoumi TA, Torchilin VP (2009) Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 15:1973–1980. https://doi.org/10.1158/1078-0432.CCR-08-2392
Ellington AD, Szostak JW (1992) Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nature 355:850–852. https://doi.org/10.1038/355850a0
Ernsting MJ, Murakami M, Roy A, Li S-D (2013) Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 172:782–794. https://doi.org/10.1016/j.jconrel.2013.09.013
Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, Amini M, Dinarvand R (2008) Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA–PEG–folate conjugate. J Drug Target 16:415–423. https://doi.org/10.1080/10611860802088630
Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136–151. https://doi.org/10.1016/j.addr.2010.04.009
Feron O (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92:329–333. https://doi.org/10.1016/j.radonc.2009.06.025
Fischgrabe J, Wulfing P (2008) Targeted therapies in breast cancer: established drugs and recent developments. Curr Clin Pharmacol 3:85–98. https://doi.org/10.2174/157488408784293732
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–30. https://doi.org/10.1038/nm0195-27
Food U, & Administration D (2003) INDs for Phase 2 and Phase 3 studies. Chemistry, manufacturing, and controls information. FDA Guidance for Industry
Frei E (2011) Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabet Metab Syndr 3:1–4. https://doi.org/10.1186/1758-5996-3-11
Genís L, Gálvez BG, Gonzalo P, Arroyo AG (2006) MT1-MMP: universal or particular player in angiogenesis? Cancer Metast Rev 25:77–86. https://doi.org/10.1007/s10555-006-7891-z
Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L (2006) Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 13:549–556. https://doi.org/10.1016/j.chembiol.2005.12.009
Ghosh S, Yesilyurt V, Savariar EN, Irvin K, Thayumanavan S (2009) Redox, ionic strength, and pH sensitive supramolecular polymer assemblies. J Polym Sci A 47:1052–1060. https://doi.org/10.1002/pola.23204
Golias T, Kery M, Radenkovic S, Papandreou I (2019) Microenvironmental control of glucose metabolism in tumors by regulation of pyruvate dehydrogenase. Int J Cancer 144:674–686. https://doi.org/10.1002/ijc.31812
Golombek SK, May J-N, Theek B, Appold L, Drude N, Kiessling F, Lammers T (2018) Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev 130:17–38. https://doi.org/10.1016/j.addr.2018.07.007
Gosk S, Moos T, Gottstein C, Bendas G (2008) VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. BBA-Biomembranes 1778:854–863. https://doi.org/10.1016/j.bbamem.2007.12.021
Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer RS, Farokhzad OC (2007) Targeted nanoparticles for cancer therapy. Nano Today 2:14–21. https://doi.org/10.1016/S1748-0132(07)70083-X
Gullotti E, Yeo Y (2009) Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 6:1041–1051. https://doi.org/10.1021/mp900090z
Hafner A, Lovrić J, Lakoš GP, Pepić I (2014) Nanotherapeutics in the EU: an overview on current state and future directions. Int J Nanomedicine 9:1005. https://doi.org/10.2147/IJN.S55359
Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–38
He H, Liu L, Morin EE, Liu M, Schwendeman A (2019) Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures. Acc Chem Res 52:2445–2461. https://doi.org/10.1021/acs.accounts.9b00228
Heldin C-H, Rubin K, Pietras K, Östman A (2004) High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer 4:806–813. https://doi.org/10.1038/nrc1456
Hicke BJ, Stephens AW (2000) Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 106:923–928. https://doi.org/10.1172/JCI11324
Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H, Kaiser WA (2002) Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Investig Radiol 37:580–586
Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95:4607–4612. https://doi.org/10.1073/pnas.95.8.46070
Hossen S, Hossain MK, Basher MK, Mia MNH, Rahman MT, Uddin MJ (2019) Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J Adv Res 15:1–18. https://doi.org/10.1016/j.jare.2018.06.005
Hua S, de Matos MBC, Metselaar JM, Storm G (2018) Current trends and challenges in the clinical translation of Nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol 9:790. https://doi.org/10.3389/fphar.2018.00790
Huo S, Jin S, Ma X, Xue X, Yang K, Kumar A, Wang PC, Zhang J, Hu Z, Liang X-J (2014) Ultrasmall gold nanoparticles as carriers for nucleus-based gene therapy due to size-dependent nuclear entry. ACS Nano 8:5852–5862. https://doi.org/10.1021/nn5008572
Ireson CR, Kelland LR (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5:2957–2962. https://doi.org/10.1158/1535-7163.MCT-06-0172
Jaafar-Maalej C, Elaissari A, Fessi H (2012) Lipid-based carriers: manufacturing and applications for pulmonary route. Expert Opin Drug Deliv 9:1111–1127. https://doi.org/10.1517/17425247.2012.702751
Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47:3039–3051
Juthi AZ, Aquib M, Farooq MA, Ghayas S, Khalid F, Boafo GF, Wande DP, Khan DH, Bithi TZ, Bavi R, Wang B (2020) Theranostic applications of smart nanomedicines for tumor-targeted chemotherapy: a review. Environ Chem Lett 18:1509–1527. https://doi.org/10.1007/s10311-020-01031-8
Kakkar V, Kumar M, Saini K (2018) Nanoceuticals governance and market review. Environ Chem Lett 16(4):1293–1300. https://doi.org/10.1007/s10311-018-0754-3
Khiavi MA, Safary A, Barar J, Ajoolabady A, Somi MH, Omidi Y (2020) Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer. Cell Mol Life Sci 77:997–1019. https://doi.org/10.1007/s00018-019-03305-z
Kim D, Lee ES, Oh KT, Gao ZG, Bae YH (2008) Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 4:2043–2050. https://doi.org/10.1002/smll.200701275
Kim TH, Jiang H-H, Youn YS, Park CW, Lim SM, Jin C-H, Tak KK, Lee HS, Lee KC (2011) Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand–loaded human serum albumin nanoparticles with improved stability and tumor distribution. J Pharm Sci 100:482–491. https://doi.org/10.1002/jps.22298
Kirn DH, Thorne SH (2009) Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9:64–71. https://doi.org/10.1038/nrc2545
Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J (2007) Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120:18–26. https://doi.org/10.1016/j.jconrel.2007.03.012
Kono K (2001) Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev 53:307–319. https://doi.org/10.1016/S0169-409X(01)00204-6
Kraft JC, Freeling JP, Wang Z, Ho RJ (2014) Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 103:29–52. https://doi.org/10.1002/jps.23773
Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, Storm G (2009) Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30:3466–3475. https://doi.org/10.1016/j.biomaterials.2009.02.040
Lammers T, Kiessling F, Hennink WE, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161:175–187. https://doi.org/10.1016/j.jconrel.2011.09.063
Leamon CP, Reddy JA (2004) Folate-targeted chemotherapy. Adv Drug Deliv Rev 56:1127–1141. https://doi.org/10.1016/j.addr.2004.01.008
Lee ES, Na K, Bae YH (2003) Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release 91:103–113. https://doi.org/10.1016/S0168-3659(03)00239-6
Liu J, Li J, Rosol TJ, Pan X, Voorhees JL (2007) Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro. Phys Med Biol 52:4739. https://doi.org/10.1088/0031-9155/52/16/002
Lu J, Jackson JK, Gleave ME, Burt HM (2008) The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother Pharm 61:997–1005. https://doi.org/10.1007/s00280-007-0557-x
Maeda H (2015) Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 91:3–6. https://doi.org/10.1016/j.addr.2015.01.002
Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47–61. https://doi.org/10.1016/S0168-3659(01)00309-1
Maeda H, Bharate G, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409–419. https://doi.org/10.1016/j.ejpb.2008.11.010
Marcucci F, Lefoulon F (2004) Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov Today 9:219–228. https://doi.org/10.1016/S1359-6446(03)02988-X
Massey KA, Schnitzer JE (2010) Caveolae and cancer. In: Liersch R, Berdel W, Kessler T (eds) Angiogenesis inhibition, book -recent results in cancer research. Springer, Berlin/Heidelberg, pp 217–231. https://doi.org/10.1007/978-3-540-78281-0_13
Meng F, Cheng R, Deng C, Zhong Z (2012) Intracellular drug release nanosystems. Mater Today 15:436–442. https://doi.org/10.1016/S1369-7021(12)70195-5
Misra R, Sahoo SK (2010) Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 39:152–163. https://doi.org/10.1016/j.ejps.2009.11.010
Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR (2005) Targeting tumor angiogenic vasculature using polymer–RGD conjugates. J Control Release 102:191–201. https://doi.org/10.1016/j.jconrel.2004.09.023
Mohanty C, Das M, Kanwar RJ, Sahoo KS (2011) Receptor mediated tumor targeting: an emerging approach for cancer therapy. Curr Drug Deliv 8:45–58
Mok H, Veiseh O, Fang C, Kievit FM, Wang FY, Park JO, Zhang M (2010) pH-Sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol Pharm 7:1930–1939. https://doi.org/10.1021/mp100221h
More MP, Deshmukh PK (2020) Development of amine-functionalized superparamagnetic iron oxide nanoparticles anchored graphene nanosheets as a possible theranostic agent in cancer metastasis. Drug Deliv Transl Res 10:862–877. https://doi.org/10.1007/s13346-020-00729-0
More MP, Pardeshi SR, Pardeshi C, Sonawane GA, Shinde MN, Deshmukh PK, Naik JB, Kulkarni AD (2021) Recent advances in phytochemical based nano-formulation for drug resistant cancer. Med Drug Discov:100082. https://doi.org/10.1016/j.medidd.2021.100082
Naqvi AA, Mohammad T, Hasan GM, Hassan M (2018) Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships. Curr Top Med Chem 18:1755–1768. https://doi.org/10.2174/1568026618666181025114157
Narang A, Chang R-K, Hussain MA (2013) Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. J Pharm Sci 102:3867–3882. https://doi.org/10.1002/jps.23691
Newton JR, Kelly KA, Mahmood U, Weissleder R, Deutscher SL (2006) In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia 8:772–780. https://doi.org/10.1593/neo.06331
Ngamcherdtrakul W, Morry J et al (2015) Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv Funct Mater 25:2646–2659. https://doi.org/10.1002/adfm.201404629
Nikam AN, More MP, Pandey AP, Patil PO, Patil AG, Deshmukh PK (2020) Design and development of thiolated graphene oxide nanosheets for brain tumor targeting. Int J Polym Mater 69:611–621. https://doi.org/10.1080/00914037.2019.1596911
Nizzero S, Ziemys A, Ferrari M (2018) Transport barriers and oncophysics in cancer treatment. Trends Cancer 4:277–280. https://doi.org/10.1016/j.trecan.2018.02.008
Nord K, Gunneriusson E, Ringdahl J, Ståhl S, Uhlén M, Nygren P-Å (1997) Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat Biotechnol 15:772–777. https://doi.org/10.1038/nbt0897-772
Oh JY, Kim HS, Palanikumar L, Go EM, Jana B, Park SA, Kim HY, Kim K, Seo JK, Kwak SK (2018) Cloaking nanoparticles with protein corona shield for targeted drug delivery. Nat Commun 9:1–9. https://doi.org/10.1038/s41467-018-06979-4
Padhi S, Behera A (2020) Nanotechnology based targeting strategies for the delivery of Camptothecin. In: Ankit S, Panda Amulya K, Eric L (eds) Pharmaceutical technology for natural products delivery, impact of nanotechnology. Springer Nature, pp 243–272
Padhi S, Mirza M, Verma D, Khuroo T, Panda A, Talegaonkar S et al (2015) Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro behavior and tumor amelioration potential. Drug Deliv 23:2827–2837. https://doi.org/10.3109/10717544.2015.1105323
Park K (2017) The drug delivery field at the inflection point: time to fight its way out of the egg. J Control Release 267:2–14. https://doi.org/10.1016/j.jconrel.2017.07.030
Park B-H, Hwang T, Liu T-C, Sze DY, Kim J-S, Kwon H-C, Oh SY, Han S-Y, Yoon J-H, Hong S-H (2008) Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 9:533–542. https://doi.org/10.1016/S1470-2045(08)70107-4
Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722–727. Pubmed: 10676659
Pasut G, Canal F, Dalla Via L, Arpicco S, Veronese FM, Schiavon O (2008) Antitumoral activity of PEG–gemcitabine prodrugs targeted by folic acid. J Control Release 127:239–248. https://doi.org/10.1016/j.jconrel.2008.02.002
Patil Y, Sadhukha T, Ma L, Panyam J (2009) Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 136:21–29
Patnaik S, Gorain B, Padhi S, Choudhury H, Gabr G, Md S et al (2021) Recent update of toxicity aspects of nanoparticulate systems for drug delivery. Eur J Pharm Biopharm 161:100–119. https://doi.org/10.1016/j.ejpb.2021.02.010
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760. https://doi.org/10.1038/nnano.2007.387
Pérez-Herrero E, Fernández-Medardem A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79. https://doi.org/10.1016/j.ejpb.2015.03.018
Pestourie C, Tavitian B, Duconge F (2005) Aptamers against extracellular targets for in vivo applications. Biochimie 87:921–930. https://doi.org/10.1016/j.biochi.2005.04.013
Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27:3889–3900. https://doi.org/10.1038/onc.2008.35
Pulkkinen M, Pikkarainen J, Wirth T, Tarvainen T, Haapa-aho V, Korhonen H, Seppälä J, Järvinen K (2008) Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin–biotin technology: formulation development and in vitro anticancer activity. Eur J Pharm Biopharm 70:66–74. https://doi.org/10.1016/j.ejpb.2008.04.018
Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS, Davis ME, Brewster M, Janicot M, Janssens B (2004) Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther 3:641–650. https://doi.org/10.4161/cbt.3.7.918
Rampling R, James A, Papanastassiou V (2004) The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. J Neurol Neurosurg Psychiatry 75:ii24–ii30. https://doi.org/10.1136/jnnp.2004.040535
Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2:373–383. https://doi.org/10.1021/mp050032z
Sahoo SK, Ma W, Labhasetwar V (2004) Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112:335–340. https://doi.org/10.1002/ijc.20405
Saiki I, Yoneda J, Azuma I, Fujii H, Abe F, Nakajima M, Tsuruo T (1993) Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 54:137–143. https://doi.org/10.1002/ijc.2910540122
Sainz V, Conniot J, Matos AI, Peres C, Zupanǒiǒ E, Moura L, Silva LC, Florindo HF, Gaspar RS (2015) Regulatory aspects on nanomedicines. Biochem Biophys Res Commun 468:504–510. https://doi.org/10.1016/j.bbrc.2015.08.023
Sanz L, Qiao J, Vile RG, Álvarez-Vallina L (2005) Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all? Curr Gene Ther 5:63–70. https://doi.org/10.2174/1566523052997479
Schroeder A, Kost J, Barenholz Y (2009) Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem Phys Lipids 162:1–16. https://doi.org/10.1016/j.chemphyslip.2009.08.003
Shadidi M, Sioud M (2003) Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 6:363–371. https://doi.org/10.1016/j.drup.2003.11.002
Sharma H, Mishra PK, Talegaonkar S, Vaidya B (2015) Metal nanoparticles: a theranostic nanotool against cancer. Drug Discov Today 20:1143–1151. https://doi.org/10.1016/j.drudis.2015.05.009
Simon SM (1999) Role of organelle pH in tumor cell biology and drug resistance. Drug Discov Today 4:32–38. https://doi.org/10.1016/S1359-6446(98)01276-8
Singh NA (2017) Nanotechnology innovations, industrial applications and patents. Environ Chem Lett 15:185–191. https://doi.org/10.1007/s10311-017-0612-8
Sinha R, Kim GJ, Nie S, Shin DM (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5:1909–1917. https://doi.org/10.1158/1535-7163.MCT-06-0141
Soroceanu L, Gillespie Y, Khazaeli M, Sontheimer H (1998) Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 58:4871–4879. Pubmed ID - 9809993
Soudy R, Etayash H, Bahadorani K, Lavasanifar A, Kaur K (2017) Breast cancer targeting peptide binds keratin 1: a new molecular marker for targeted drug delivery to breast cancer. Mol Pharm 14:593–604. https://doi.org/10.1021/acs.molpharmaceut.6b00652
Stollman T, Ruers T, Oyen W, Boerman O (2009) New targeted probes for radioimaging of angiogenesis. Methods 48:188–192. https://doi.org/10.1016/j.ymeth.2009.03.006
Stroescu C, Herlea V, Dragnea A, Popescu I (2006) The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J Gastrointest Liver 15:9
Sudimack J, Lee RJ (2000) Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41:147–162. https://doi.org/10.1016/S0169-409X(99)00062-9
Sutherland RM (1988) Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240:177–184. https://doi.org/10.1126/science.2451290
Taheri A, Dinarvand R, Atyabi F, Nouri F, Ahadi F, Ghahremani MH, Ostad SN, Borougeni AT, Mansoori P (2011) Targeted delivery of methotrexate to tumor cells using biotin functionalized methotrexate-human serum albumin conjugated nanoparticles. J Biomed Nanotechnol 7:743–753. https://doi.org/10.1166/jbn.2011.1340
Thakar SB, Ghorpade PN, Shaker B, Lee J, Na D (2021) Gas-mediated cancer therapy combined with starvation therapy, ultrasound therapy, chemotherapy, radiotherapy, and photodynamic therapy: a review. Environ Chem Lett 19:2981–2993. https://doi.org/10.1007/s10311-021-01218-7
Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz YC, Tamarkin L, Desai N (2014) Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci 1313:35–56. https://doi.org/10.1111/nyas.12403
Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. In: Schäfer-Korting M (ed) Drug delivery: handbook of experimental pharmacology. Springer, Berlin/Heidelberg, pp 3–53. https://doi.org/10.1007/978-3-642-00477-3_1
Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–135. https://doi.org/10.1016/j.addr.2010.03.011
Ulrich H, Martins AHB, Pesquero JB (2005) RNA and DNA aptamers in cytomics analysis. Current Protoc Cytom 33:7.28.21–7.28.39. https://doi.org/10.1002/cyto.a.20056
Van Sluis R, Bhujwalla ZM, Raghunand N, Ballesteros P, Alvarez J, Cerdán S, Galons JP, Gillies RJ (1999) In vivo imaging of extracellular pH using 1H MRSI. Magn Reson Med 41:743–750. https://doi.org/10.1002/(SICI)1522-2594(199904)41:4<743::AID-MRM13>3.0.CO;2-Z
Veiseh M, Gabikian P, Bahrami S-B, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ (2007) Tumor paint: a chlorotoxin: Cy5. 5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 67:6882–6888. https://doi.org/10.1158/0008-5472.CAN-06-3948
Venning FA, Wullkopf L, Erler JT (2015) Targeting ECM disrupts cancer progression. Front Oncol 5:224. https://doi.org/10.3389/fonc.2015.00224
Verheul HM, Pinedo HM (2000) The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGFReceptor kinase inhibitors. Clin Breast Cancer:S80–S84. https://doi.org/10.3816/CBC.2000.s.015
Wang Z, Chui W-K, Ho PC (2009) Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm Res 26:1162–1171. https://doi.org/10.1007/s11095-009-9837-y
Wang H, Wei J, Yang C, Zhao H, Li D, Yin Z, Yang Z (2012) The inhibition of tumor growth and metastasis by self-assembled nanofibers of taxol. Biomaterials 33:5848–5853. https://doi.org/10.1016/j.biomaterials.2012.04.047
Wikman M, Steffen A-C, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Ståhl S (2004) Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 17:455–462. https://doi.org/10.1093/protein/gzh053
Wilson DS, Szostak JW (1999) In vitro selection of functional nucleic acids. Annu Rev Biochem 68:611–647. https://doi.org/10.1146/annurev.biochem.68.1.611
Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, Agarwal RG, Lam KS (2011) The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32:3435–3446. https://doi.org/10.1016/j.biomaterials.2011.01.021
Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y, Fang X (2011) Angiopep-conjugated poly (ethylene glycol)-co-poly (ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32:4293–4305. https://doi.org/10.1016/j.biomaterials.2011.02.044
Yoo J, Park C, Yi G, Lee D, Koo H (2019) Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers 11:640. https://doi.org/10.3390/cancers11050640
Yu MK, Park J, Jon S (2012) Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2:3. https://doi.org/10.7150/thno.3463
Zhong S, Ling Z, Zhou Z, He J, Ran H, Wang Z, Zhang Q, Song W, Zhang Y, Luo J (2020) Herceptin-decorated paclitaxel-loaded poly (lactide-co-glycolide) nanobubbles: ultrasound-facilitated release and targeted accumulation in breast cancers. Pharm Dev Technol 25:454–463. https://doi.org/10.1080/10837450.2019.1709500
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
More, M.P. et al. (2022). Passive and Active Targeting for Solid Tumors. In: Padhi, S., Behera, A., Lichtfouse, E. (eds) Polymeric nanoparticles for the treatment of solid tumors. Environmental Chemistry for a Sustainable World, vol 71. Springer, Cham. https://doi.org/10.1007/978-3-031-14848-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-031-14848-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14847-7
Online ISBN: 978-3-031-14848-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)